Market Place
Sourcing Support
Vivoryon Therapeutics N.V. Reports 2024 Financial Results
28 Apr 2025 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. Signs EUR 15 Million Financing Deal
24 Apr 2025 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Report 2024 Results on April 29
17 Apr 2025 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. Shares Highlights from R&D Update
19 Feb 2025 //
GLOBENEWSWIRE
Vivoryon To Host Virtual R&D Update With KOLs On Feb 18
11 Feb 2025 //
GLOBENEWSWIRE
Vivoryon Strengthens R&D Pipeline for Kidney Disease Treatments
14 Jan 2025 //
GLOBENEWSWIRE
Vivoryon Reports Q3 2024 Results & Varoglutamstat in Kidney Disease
10 Dec 2024 //
GLOBENEWSWIRE
Vivoryon`s Alzheimer`s asset suffers 2nd phase 2 fail
09 Dec 2024 //
FIERCE BIOTECH
Vivoryon`s Ph 2 Data Supporting Varoglutamstat’s Kidney Function
08 Dec 2024 //
GLOBENEWSWIRE
Vivoryon To Report Q3 2024 Results & Progress On Dec 10
04 Dec 2024 //
GLOBENEWSWIRE
Vivoryon Therapeutics Presents Positive Phase 2b Results in ASN
26 Oct 2024 //
GLOBENEWSWIRE
Vivoryon Announces Presentation At ASN Kidney Week 2024
11 Oct 2024 //
GLOBENEWSWIRE
Vivoryon Shares Highlights From Kidney Disease KOL Virtual Event
01 Oct 2024 //
GLOBENEWSWIRE
Vivoryon To Report H1 2024 Results And Host KOL Event
05 Sep 2024 //
GLOBENEWSWIRE
Vivoryon Therapeutics Announces Completes Share Capital Reduction
05 Sep 2024 //
GLOBENEWSWIRE
Vivoryon Announces Varoglutamstat Data In Diabetic Kidney Disease
18 Jul 2024 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. To Host R&D Update Call
09 Jul 2024 //
BIOSPACE
Vivoryon Therapeutics Reports Outcome of 2024 Annual General Meeting
21 Jun 2024 //
GLOBENEWSWIRE
Vivoryon Q1 2024 Financials: Kidney Disease Strategic Focus Reinforced
23 May 2024 //
GLOBENEWSWIRE
Vivoryon To Report Q1 2024 Results, Operational Progress On May 23
15 May 2024 //
GLOBENEWSWIRE
Vivoryon 2024 AGM On June 21
08 May 2024 //
GLOBENEWSWIRE
Vivoryon Reports 2023 Results, Pipeline Updates
24 Apr 2024 //
GLOBENEWSWIRE
Vivoryon To Report FY 2023 Results, Progress On 4/24
15 Apr 2024 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
15 Mar 2024 //
GLOBENEWSWIRE
Vivoryon Alzheimer’s drug fails phase 2 trial, crashing stock
04 Mar 2024 //
FIERCE BIOTECH
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
08 Jan 2024 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results
28 Nov 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
07 Nov 2023 //
GLOBENEWSWIRE
Vivoryon Provides Comprehensive Progress Report for VaroglutamstatProgram
26 Oct 2023 //
GLOBENEWSWIRE
Vivoryon Reports Positive Outcome from Board for Varoglutamstat
23 Oct 2023 //
GLOBENEWSWIRE
Vivoryon N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
17 Oct 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. Announces Virtual R&D Event
05 Oct 2023 //
GLOBENEWSWIRE
Vivoryon General Meeting Approved Appointment of Executive Directors to Board
15 Sep 2023 //
GLOBENEWSWIRE
Vivoryon Reports H1 2023 Financial Results and Highlights Operational Progress
07 Sep 2023 //
GLOBENEWSWIRE
Vivoryon to Report Half Year 2023 FYR & Operational Progress on Sept07, 2023
31 Aug 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics Announces Proposed Appointment of Dr. Frank Weber as CEO
04 Aug 2023 //
GLOBENEWSWIRE
Vivoryon Meeting to Confirm Executive Director Appointments Held on September 15
04 Aug 2023 //
GLOBENEWSWIRE
Vivoryon Shares Development Update Highlighting Progress of Varoglutamstat
16 Jul 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
21 Jun 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. Announces CEO Transition Plan
15 Jun 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
01 Jun 2023 //
GLOBENEWSWIRE
Vivoryon Successfully Completes Private Placement Raising EUR 25 Million
26 May 2023 //
GLOBENEWSWIRE
Vivoryon Launches Capital Increase by Way of an Bookbuild Offering
25 May 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. Reports Q1 2023 FYR & Highlights Operational Progress
16 May 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Report Q1 2023 FYR & Operational Progress
09 May 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting
09 May 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition
01 May 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
24 Apr 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. Reports Full Year 2022FYR and Highlights
19 Apr 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results
14 Apr 2023 //
GLOBENEWSWIRE
Vivoryon Provides Progress Update on Varoglutamstat Clinical Development
28 Mar 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
21 Feb 2023 //
GLOBENEWSWIRE
Vivoryon Therapeutics N.V. to Present at the 2023 BIO CEO & Investor Conference
03 Feb 2023 //
GLOBENEWSWIRE
Vivoryon`s stock climbs on midphase Alzheimer`s disease data
01 Aug 2022 //
FIERCEBIOTECH
